Aandeel ALT ALTIMMUNE, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Altimmune, Inc.

Aandelen

ALT

US02155H2004

Geschatte realtime Cboe BZX
Andere beurzen
 16:30:29 26-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
6,72 USD -9,31% Intraday-grafiek van Altimmune, Inc. +16,16% -38,67%
14:35 Altimmune CFO Richard Eisenstadt overleden MT
23/06 Altimmune, Inc. Presenteert gegevens van de Fase 2 MOMENTUM-studie met pemvidutide bij obesitas op de 84e Scientific Sessions van de American Diabetes Association CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Altimmune CFO Richard Eisenstadt Dies
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer
Contact Levi & Korsinsky by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions
Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
ALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers ALT
  4. Nieuws Altimmune, Inc.
  5. Andere talen